Howard Lightfoot
Overview
Explore the profile of Howard Lightfoot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
4235
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chai A, Tan Y, Ooi S, Yee P, Yee S, Lightfoot H, et al.
Cancer Res Commun
. 2024 Oct;
4(11):2919-2932.
PMID: 39360810
Mechanistically guided drug repurposing has been made possible by systematically integrating pharmacologic and CRISPR-Cas9 screen data. Our study discovers the biomarker and cell death mechanisms underpinning sensitivity toward AZD5582, an...
2.
Vis D, Jaaks P, Aben N, Coker E, Barthorpe S, Beck A, et al.
Cell Rep Med
. 2024 Aug;
5(8):101687.
PMID: 39168097
Combining drugs can enhance their clinical efficacy, but the number of possible combinations and inter-tumor heterogeneity make identifying effective combinations challenging, while existing approaches often overlook clinically relevant activity. We...
3.
Picco G, Rao Y, Al Saedi A, Lee Y, Vieira S, Bhosle S, et al.
Cancer Discov
. 2024 Apr;
14(8):1457-1475.
PMID: 38587317
Microsatellite-unstable (MSI) cancers require WRN helicase to resolve replication stress due to expanded DNA (TA)n dinucleotide repeats. WRN is a promising synthetic lethal target for MSI tumors, and WRN inhibitors...
4.
Bashi A, Coker E, Bulusu K, Jaaks P, Crafter C, Lightfoot H, et al.
Cancer Discov
. 2024 Mar;
14(5):846-865.
PMID: 38456804
Significance: We present the largest cancer drug combination screen published to date with 7 × 7 concentration response matrices for 109 combinations in more than 750 cell lines, complemented by...
5.
Chai A, Yee S, Lee H, Aziz N, Yee P, Marzuki M, et al.
Cancer Res Commun
. 2024 Feb;
4(3):645-659.
PMID: 38358347
Significance: NPC268 is the first and only EBV-positive cell line derived from a primary non-keratinizing, differentiated nasopharyngeal carcinoma, an understudied but important subtype in Southeast Asian countries. This model adds...
6.
Pacini C, Duncan E, Goncalves E, Gilbert J, Bhosle S, Horswell S, et al.
Cancer Cell
. 2024 Jan;
42(2):301-316.e9.
PMID: 38215750
Genetic screens in cancer cell lines inform gene function and drug discovery. More comprehensive screen datasets with multi-omics data are needed to enhance opportunities to functionally map genetic vulnerabilities. Here,...
7.
Goncalves E, Poulos R, Cai Z, Barthorpe S, Manda S, Lucas N, et al.
Cancer Cell
. 2022 Jul;
40(8):835-849.e8.
PMID: 35839778
The proteome provides unique insights into disease biology beyond the genome and transcriptome. A lack of large proteomic datasets has restricted the identification of new cancer biomarkers. Here, proteomes of...
8.
Price S, Bhosle S, Goncalves E, Li X, McClurg D, Barthorpe S, et al.
Sci Rep
. 2022 Apr;
12(1):5571.
PMID: 35368031
Organoid cell culture methodologies are enabling the generation of cell models from healthy and diseased tissue. Patient-derived cancer organoids that recapitulate the genetic and histopathological diversity of patient tumours are...
9.
Jaaks P, Coker E, Vis D, Edwards O, Carpenter E, Leto S, et al.
Nature
. 2022 Feb;
603(7899):166-173.
PMID: 35197630
Combinations of anti-cancer drugs can overcome resistance and provide new treatments. The number of possible drug combinations vastly exceeds what could be tested clinically. Efforts to systematically identify active combinations...
10.
Pacini C, Dempster J, Boyle I, Goncalves E, Najgebauer H, Karakoc E, et al.
Nat Commun
. 2021 Mar;
12(1):1661.
PMID: 33712601
CRISPR-Cas9 viability screens are increasingly performed at a genome-wide scale across large panels of cell lines to identify new therapeutic targets for precision cancer therapy. Integrating the datasets resulting from...